Phase 4 Hypertension Trial, Recruiting NCT04401982 Sponsor: University of Maryland, Baltimore Condition: Hypertension
Back to Hypertension

Phase 4 Hypertension Trial, Recruiting

NCT04401982
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 18 years old.
  • People who have been diagnosed with high eye pressure (ocular hypertension) or are considered a suspected glaucoma patient.
  • People who have not used any eye pressure-lowering medications (either eye drops or tablets) in the past 6 months.
  • People whose eye drainage angles are open, as confirmed by a special eye examination called gonioscopy.
  • People who have had at least one visual field (peripheral vision) test recorded within the past 6 months before joining the study.

Who may not be able to join:

  • People currently taking part in another research study that involves drugs or agents that could affect the results of this trial (confirm with trial site).
  • People who have had previous eye surgery, other than straightforward cataract surgery.
  • People with a known allergy or past bad reaction to ICG dye, shellfish, or iodine.
  • People with significant liver disease or a condition where the kidneys cannot filter waste properly (uremia).
  • People with certain types of glaucoma, including exfoliation glaucoma, pigmentary glaucoma, or a history of sudden angle-closure glaucoma.
  • People with moderate or severe loss of peripheral vision, as measured by a standard grading system used in the study.
  • People with any eye condition that would prevent clear imaging or reliable vision testing, such as clouding of the eye's lens or a tilted optic nerve.
  • People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Osamah Saeedi, MD, University of Maryland, Baltimore

Phone: (410) 328-5929

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
2 July 2026
Est. completion
17 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Episcleral Venous Blood Flow Measured by Erythrocyte-Mediated Angiography (EMA); Change in Retinal Arteriolar and Venular Blood Flow Measured by Erythrocyte-Mediated Angiography (EMA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov